Generic Drugs and Biosimilars Secure Big Savings for U.S. Patients
In 2019, generic medicines saved America’s patients $313 billion and nearly $2.2 trillion in the last decade. Biosimilar medicines also saved $2.2 billion and $4.5 billion over the past 10 years. The availability of safe, effective and affordable generics and biosimilars secures tremendous access and savings for America’s patients throughout the COVID-19 pandemic. Some key […]
Report: 2019 Generic Drug & Biosimilars Access & Savings in the U.S.
To view the latest data, view 2020 Access & Savings Report The American public is clamoring for systemic changes to address skyrocketing drug prices. Specialty drugs — a fast-growing category that includes biologics and other complex medicines — are of particular concern. These medicines account for only 2% of prescriptions but already represent almost half […]
Securing Access and Savings: By the Numbers
Now that Rich is semi-retired, he loves to go boating on the Chesapeake Bay. He takes a generic drug to control his blood pressure. On the other side of the country, Jeni is pursuing a graduate degree and enjoying California’s hiking trails. She takes a biosimilar medication to treat her pancolitis. Rich and Jeni may […]
2020 Generic Drug & Biosimilars Access and Savings in the U.S. Report
In 2019, the U.S. health care system saved $313 billion in 2019 from generics and biosimilar drugs, including $96 billion in Medicare savings and $48.5 billion in savings to Medicaid. At a time when access to reliable, affordable and high-quality prescription medication is more important than ever, generics fill 90% of prescriptions in the United […]
AAM Releases 12th Annual Access & Savings Report
Study Finds Generic Savings Totaled a Record $313 Billion in 2019 WASHINGTON, DC (September 29, 2020) — Today, the Association for Accessible Medicines (AAM), the trade association for generic and biosimilar manufacturers, released the 2020 Access & Savings Report detailing the economic benefit of generic and biosimilar drugs to America’s patients. According to the report, the […]
2020 Report
Generic Drug and Biosimilars Access and Savings in the U.S. Every year, the Association for Accessible Medicines (AAM) releases a report documenting the billions of dollars that the U.S. health care system saves through generic and biosimilar prescription medicines. Here are some highlights from the 2020 report: America’s patients and our health care system saved $313 […]
Generic Medicines Save Money for Patients and Taxpayers
AAM is the nation’s leading trade association for manufacturers and distributors of generic and biosimilar prescription medicines. Our core mission is to improve the lives of patients by advancing timely access to affordable, FDA-approved generic and biosimilar medicines. Our members provide more than 36,000 jobs at nearly 150 facilities, and manufacture more than 61 billion […]
2018 Generic Drug Access and Savings Report
The 2019 report is now available. As in previous years, the tenth edition of this annual report presents the independent findings of IQVIA regarding the savings that our companies bring about. In 2017, generics generated a total of $265 billion in savings. Savings for Medicare and Medicaid amounted to $82.7 billion and $40.6 billion, respectively, […]
Generic Drugs Are the Prescription for Savings. Don’t Take Them for Granted.
More than 9 out of 10 generic drug prescriptions are filled for $20 or less. Everybody who takes medicine to get or stay healthy can appreciate these savings, which allow patients and families to spend their money on other things that matters to them. Those savings, however, are now in jeopardy, thanks to a combination […]
Protect & Expand Competition
Generic and biosimilar medicines are saving families money and holding down government costs. The Association for Accessible Medicines (AAM), formerly known as the Generic Pharmaceutical Association, advocates for policies that ensure real competition not half-measures or window dressing. When we stop some brand drug companies from blocking or delaying competition from safe, effective and more […]
Generic Drug Prices vs. Brand Drug Prices
According to FDA estimates, generics are 80%-85% less expensive than their brand-name drug equivalents. Competition and a patient-centered orientation are what make generics and biosimilars the solution that helps people live their lives, their way. The Association for Accessible Medicines and its members give millions of Americans what they need to need to live healthier, […]
Generics: Your Prescription for Savings
More FDA-approved generic and biosimilar medicines are available now than ever before. Today, America’s patients are benefitting from significant savings at the pharmacy counter and in lower out-of-pocket costs. But those savings are increasingly at risk due to anti-competitive abuses and misguided policies that block access to lower-cost medicines. Congress can take meaningful action to […]
